Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Conditions
Interventions
Intervention1: Hormonal Therapy: Hormonal therapy will be in the form of Letrozole 2.5 mg OD started 2-3 weeks post surgery. Hormonal therapy will be continued for 5 years or till progression whicheve
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: a. Age 18 â?? 75 years b. Stage II â?? stage IV LGSC c. Patients who have undergone either upfront cytoreductive surgery or who have received neoadjuvant chemotherapy and then underwent cytoreductive surgery. d. ER and /or PR positive cases.
Exclusion criteria
Exclusion criteria: a. Patients who received chemotherapy post cytoreductive surgery. b. Recurrent cases of low-grade serous cancer of ovary/peritoneum. c. Cells showing morphological features of LGSC with moderate nuclear atypia and >= 70% cells showing diffuse strong P53 mutations or null type P53. d. ER and PR negative LGSC e. Exclude if fertility sparing conservative surgery is undertaken f. Low grade serous ovarian/fallopian tube/ cancer during pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survivalTimepoint: 3 and 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall SurvivalTimepoint: 3 and 5 years;Quality of Life Assessment by using TMH Mini Quality of Life (Qol) questionnaireTimepoint: Prior to surgery, at 6 month follow-up, and yearly thereafter till initiation of second line treatment when needed. | — |
Countries
India
Contacts
Public ContactDr T S Shylasree
Tata Memorial Centre
Outcome results
None listed